CYCC — Cyclacel Pharmaceuticals Income Statement
0.000.00%
- $2.37m
- -$0.43m
- $0.42m
- 12
- 37
- 28
- 15
Annual income statement for Cyclacel Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0.42 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 9.68 | 10.6 | 22.9 | 27.7 | 25.9 |
Operating Profit | -9.68 | -10.6 | -22.9 | -27.7 | -25.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -9.13 | -9.68 | -22.7 | -25.9 | -25.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7.83 | -8.45 | -18.9 | -21.2 | -22.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -7.83 | -8.45 | -18.9 | -21.2 | -22.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.03 | -12.4 | -19.1 | -21.4 | -22.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -148 | -51.3 | -32.1 | -28.5 | -26.7 |
Dividends per Share |